At a glance
ClinicalIndex Comparison RecordN/AUnknown· 40 target
Drug / intervention
Crizotinibdrug
Likely dose
Crizotinib 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ROS1-rearranged Non-squamous Non-small Cell Lung Cancer
In Brief
An observational study evaluating Crizotinib for Non-small Cell Lung Cancer. Targeting 40 participants across 1 site.
Detailed Summary
This study was designed to explore the efficacy and safety of Crizotinib as a first-line treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world, explore the new drug resistance mechanism of ROS1 under Crizotinib treatment and the consistency of plasma and tissue detection driving genes, and finally evaluate the mutation spectrum of plasma dynamic detection driving genes. In predicting the risk of disease progression.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
N/AUnknownOverdue
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedAug 2018
Primary CompletionDec 2024
Study CompletionDec 2025
TodayJul 2026
First PostedAug 24, 2018
Enrollment StartAug 1, 2018
Primary CompletionDec 31, 2024
Study CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 6.4 yearsPosted 7.9 years ago
Interventions
Crizotinibdrug
Crizotinib Cap 250 mg po bid